Curated News
By: NewsRamp Editorial Staff
June 05, 2025
Bio-Path Holdings Advances RNAi Therapeutics with DNAbilize® Platform
TLDR
- Bio-Path Holdings' innovative DNAbilize® technology and diverse pipeline, including prexigebersen for AML, positions it as a potential leader in RNAi therapeutics, offering a competitive edge in biotech investments.
- Bio-Path Holdings utilizes its DNAbilize® platform to deliver antisense oligonucleotides with enhanced stability and uptake, currently testing prexigebersen in Phase 2 trials for AML and exploring treatments for solid tumors and metabolic diseases.
- Bio-Path Holdings' research into RNAi therapeutics like prexigebersen could revolutionize treatment for AML, solid tumors, and metabolic diseases, significantly improving patient outcomes and quality of life.
- Discover how Bio-Path Holdings' DNAbilize® technology is breaking barriers in drug delivery, with promising candidates for leukemia, solid tumors, and even obesity and diabetes treatments.
Impact - Why it Matters
The advancements by Bio-Path Holdings in RNAi therapeutics could revolutionize the treatment of cancer and metabolic diseases, offering hope to patients with limited options. The company's innovative DNAbilize® platform addresses key challenges in drug delivery, potentially leading to more effective and safer treatments. This news is crucial for investors, healthcare professionals, and patients alike, as it highlights the potential for groundbreaking therapies in the near future.
Summary
Bio-Path Holdings, Inc., a clinical-stage biotechnology company, is making strides in the development of RNA interference (RNAi) therapeutics with its proprietary DNAbilize® platform. The company's lead candidate, prexigebersen (BP1001), is in Phase 2 trials for acute myeloid leukemia (AML), with a modified version, BP1001-A, showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein for blood cancers and solid tumors, while BP1003, a STAT3 inhibitor, is in pre-clinical development for pancreatic cancer. Bio-Path's innovative DNAbilize® technology enhances drug stability and cellular uptake, positioning the company as a pioneer in the field. With strategic relationships, including with The MD Anderson Cancer Center, and a strong IP position, Bio-Path is poised for significant advancements in cancer treatment and metabolic diseases.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Bio-Path Holdings Advances RNAi Therapeutics with DNAbilize® Platform
